Lung cancer recurrent

Z. Keidar, N. Haim, L. Guralnik, M. Wollner, R. Bar-Shalom, A. Ben-Nun, O. Israel, PET/CT using F-FDG in suspected lung cancer recurrence Diagnostic value and impact on patient management, J. Nucl. Med. 45(10) (2004) 1640-1646. 

Small cell lung cancer typically presents as extensive disease (approximately 60% to 70% of new cases) and progresses very quickly. Small cell carcinomas are very responsive to chemotherapy and radiation. Radiotherapy became the standard in 1969, when a randomized trial showed that it offered the potential for cure, whereas surgery did not.20 For the vast majority of patients, chemotherapy with or without radiotherapy is the treatment of choice. Even after a complete response to therapy, the cancer usually recurs within 6 to 8 months, and survival time following recurrence is typically short ( 4 months). This yields a typical survival rate of 14 to 20 months for limited disease and 8 to 13 months for extensive disease.33 Table 87-6 illustrates the general treatment path of SCLC. 

Coy P, Hodson BM, Payne D, et al. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small-cell lung cancer. Initial results of a Canadian multicenter randomized trial. Int J Radiat Oncol Biol Phys 1987 14 219-226. 

Liengswangwong V, Bonner J, Shaw E, et al. Limited-stage small-cell lung cancer patterns of intratho-racic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994 12 496-502. 

Arriagada R, Pellac-Cosset B, Cueto Ladron de Guevara J, et al. Alternating radiotherapy and chemotherapy schedules in limited small-cell lung cancer analyses of local chest recurrences. Radiother Oncol 1991 20 91-98. 

S. K. Kelley, and A. Sandler. 2005. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-l/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer./. Clin. Oncol. 23 2544-2555. 

Mitsudomi T et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 2513-2520... 

Buccheri G, Ferrigno D, Identifying patients at risk of early postoperative recurrence of lung cancer A new use of the old CEA test, Ann. Thorac. Surg., 75 973-980, 2003. 

Ishikawa A, Motohashi S, Ishikawa E, Euchida H, Higashino K, Otsuji M, lizasa T, Nakayama T, Taniguchi M, Eujisawa T. A phase I smdy of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 2005 11 1910-1917. 

The long-term consequences from mustard gas exposure, particularly at low doses, are unknown. However, a one-time high-dose exposure can result in chronic and recurrent lung and eye problems. Mustard gas is also a known carcinogen, and can cause lung cancer later in life. The ability to cause birth defects in the children of exposed adults is not presently known however, it has the potential to be teratogenic. 

STAGE IV METASTATIC OR RECURRENT AND UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER... 

Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995 109 120-129. 

R. Feld, L.V. Rubinstein, T.H. Weisenberger and the Lung Cancer Study Group (1984). Sites of recurrence in resected stage I Non-Small-Cell Lung Cancer. A guide for future studies. J. Clin. Oncol., 2, 1352-1358. 

G. Sozzi, M. Oggionno, L. Alasio, et al. (2002). Molecular changes track recurrence and progression of bronchial pre-cancerous lesions. Lung Cancer, 37, 267-270. 

---